Newsletter

Stay up to date on all things IBS. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Fecal Metabolome and the Intestinal Microbiota in IBS

December 20, 2019

Overview

This study examines the relationship between fecal bile acids, SCFA, and gut microbiota in patients with irritable bowel syndrome (IBS). Through the study, investigators hope to not only determine if SCFA and bile acids play a role in IBS but also see if there is a connection between colonic transit and fecal microbiota. All of these findings could help determine clinical strategies for treatment and diagnosis of IBS.

 

Study Information

Investigators are looking for 90 participants who meet the inclusion criteria to participate in this study that began in July 2016 and is scheduled to be completed by July 2021. There are three cohorts (groups) in the study: patients with IBS-C (constipation), patients with IBS-D (diarrhea) and healthy control patients. All three groups will undergo an x-ray of the abdomen to assess colonic transit.

 

Inclusion Criteria

 

  • Patients with IBS
  • Ages 18-65
  • Fulfilling Rome IV criteria and asymptomatic controls with no prior history of GI disease or symptoms.
  • On a stable and consistent diet regimen and not following an extreme diet intervention such as gluten-free or a low FODMAP diet at the time of study participation.

 

Exclusion Criteria

 

  • Participants with microscopic/lymphocytic/collagenous colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, history of liver disease or history of elevated AST/ALT > 2.0x the upper limit of normal
  • Prior radiation therapy of the abdomen or abdominal surgeries with the exception of appendectomy or cholecystectomy > 6 months prior to study initiation
  • Ingestion of any prescription, over the counter, or herbal medications which can affect GI transit or study interpretation (e.g. opioids, narcotics, anticholinergics, norepinephrine reuptake inhibitors, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, bile acid sequestrants) within 6 months of study initiation for asymptomatic volunteers or within 2 days before study initiation for IBS patients
  • Any females who are pregnant or trying to become pregnant or breast-feeding
  • Antibiotic usage within 3 months prior to study participation
  • Prebiotic or probiotic usage within the 2 weeks prior to study initiation
  • Use of tobacco products within the past 6 months.

 

Location

Indiana University Hospital
Indianapolis, Indiana, United States, 46202
Contact: Anita Gupta, MBBS, MPH 317-948-9227 anigupta@iu.edu

 

Sponsors/Collaborators

Indiana University

Clinical Trials

View All Clinical Trials

Effect of Curcumin on Gut Microbiota in IBS

This study aims to investigate how the food supplement curcumin affects children with irritable bowel syndrome…

Effect of Tai Chi as Treatment for IBS-C

This study investigates how effective the practice of Tai Chi is in reducing symptoms associated with irritable…

Psychological Therapies and Functional Bowel Disorders

This study aims to investigate how psychological therapies affect people with functional bowel disorders like…

Acceptability and Efficacy of the Zemedy App for IBS

This is a study that investigates whether the self-help app Zemedy is helpful for improving the quality of life of…

Vitamin D Supplementation in IBS

This trial investigates the effect of supplementing with Vitamin D on irritable bowel syndrome (IBS) symptoms for…

Efficacy and Safety of IBS Digital Behavioral Treatment

This study investigates the EASITx treatment for irritable bowel syndrome (IBS). The treatment is a medical device…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend